Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The authorized shares (AS) are a function of the pps and dollar amount of convertible loans. When it appeared the pps could go to $.0001, they had to allocate enough shares to be able to convert all of the loans. At the last 10-Q they reported that they had a little over $1,000,000 in convertible loans. Converting all those loans at $.0001 would require...
$1,000,000 / $.0001/share = 10,000,000,000 shares AS
This doesn't mean that all of the loans (or even any of the loans) were actually converted. Think of it as always having enough collateral to cover your loans.
New PR Today...
ALYI – Alternet Systems Kicks Off $100 Million Electric Vehicle Production Facility Project
DALLAS, Nov. 14, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Alternet Systems, Inc. (USOTC: ALYI) today announced IW Global ( www.IW-Global.com ) and ALYI’s Kenyan electric vehicle production partner will all meet in Dallas, Texas on Monday, November 18, 2019 to kick-off a joint project to raise $100 million to fund infrastructure for the ongoing production of electric vehicles in Africa. Separately, ALYI has already initiated and continues to develop $300 million in electric vehicle projects in Africa targeting the shared ride market. The project with IW Global is intended to substantially expand ALYI’s electric vehicle initiative in Africa.
IW Global has proposed launching and managing an Initial Coin Offering (ICO) on ALYI’s behalf specifically targeted at raising $100 million to fund infrastructure for electric vehicle production in Africa. IW Global, a well-established technology firm with a wide breadth of experience spanning projects for NASA and more has recently implemented multiple blockchain solutions, has proposed launching and managing an Initial Coin Offering (ICO) on ALYI’s behalf specifically targeted at raising $100 million to fund infrastructure for electric vehicle production in Africa.
ALYI and IW Global have formulated a plan whereby, ALYI’s production and marketing partners in Kenya will form a new company (NewCo) with the specific focus of building a new, state of the art electric vehicle production plant. This NewCo will be a separate company apart from ALYI but exclusively contracted by ALYI for producing ALYI designed vehicles. The NewCo is the business entity that would initiate the proposed ICO. The funds would be dedicated to 1. Building the plant and 2. Funding the production of ALYI’s vehicles. A successful ICO would permit ALYI to substantially accelerate and expand upon its initial $300 million in existing electric vehicle projects.
ALYI has engaged legal counsel to ensure the cryptocurrency launch would be executed in compliance with prevailing regulatory guidelines.
ALYI has engaged Goldman Small Cap Research to conduct a survey with first time and experienced cryptocurrency investors in conjunction with a potential $100 million initial coin offering (ICO) that would provide strategic financing to fund a major expansion of the company’s electric vehicle developments.
Ethereum is the proposed underling platform for the ALYI cryptocurrency launch. The Ethereum platform and blockchain is the most reliable existing blockchain and is supported by the Ethereum Foundation, based in Zug, Switzerland and the Ethereum Enterprise Alliance based in the USA with members like Microsoft, Intel, Mastercard, UBS, BBVA, Banco Santander, among others. IW Global is experienced with Ethereum and has launched previous cryptocurrencies build on the Ethereum platform.
ALYI management plans to publish continued progress reports as the ICO strategy develops.
For more information, please visit: www.alternetsystemsinc.com
Synthetic Genomics, Inc now owns 5.2% of Armata.
ARMP SC 13G
Synthetic Genomics, Inc website
Synthetic Genomics, Inc. (SGI) is a leader in the genomics revolution. SGI was founded in 2005 by genomics pioneers Craig Venter, Ph.D., and Nobel Laureate Hamilton Smith, M.D., shortly after the completion of the Human Genome Project, which mapped the human genome for the first time. Since then, scientists and engineers have dramatically improved the accuracy and reduced the cost associated with reading the sequence of DNA code — the order of the As, Cs, Ts, and Gs that make up an organism’s genome...
...Phage therapy has the potential to treat multidrug-resistant bacterial infections. Engineered phage can solve inherent limitations of natural phage, such as narrow host-range and resistance development. Synthetic Genomics has developed a proprietary bacteriophage engineering platform to address the inherent limitations of natural phage as a therapeutic. Armata Pharmaceuticals is deploying the Synthetic Genomics IP to generate clinical candidates and bacteriophage therapies.
I picked up 900,000 shares on that 100 million dump yesterday.
POSSIBLE 7 BILLION SHARES
WHO HOLDS HOLDS 7 BILLION SHARES ?????
Oh, I see, I must have missed it before. Definite proof of a scam. A company buys another company, pays the owners, then employs them and their employees to help run things. Such deals never happen. It must be insider enrichment. SMHLMAO
The company picked up a team of programmers and the software wasn't worthless. Both the programmers and software became part of OBITX and forms the basis for any future products/software that OBITX produces. The purchase was paid for with mCig shares. The value, roughly $3 million, was transferred to mCig shareholders as the OBITX dividend. You can disagree about whether it was a smart purchase but show us, oh wise one, the mechanics of how Paul made money off of this.
There's no way to know how many shares are currently outstanding. We can only guess. At the time of the last PR OS update, the pps was between $.0030 and .0020. A lot of convertible debt has already passed it's due date so it really depends on how willing the note holders were to hang on while the pps dropped over the last few months. They seemed pretty patient up until then and I'm sure SIML management has been doing their best to keep them from panicking.
According to the Form 4's...
Hawkins sold 300,000 shares and received roughly $45,000 (his annual salary). In the meantime, the remaining 11,054,653 shares he owned lost roughly $1.2 million in value.
Paul cashed in roughly $50,000 (his annual salary) by selling about 350,000 shares. In the meantime, the rest of his 85,667,138 shares lost roughly $10 million in value.
Boy we should all be so good at making money by scamming others. Maybe you should try it some time. SMHLMAO
BTW, How does paying other people to buy their work product benefit Paul or Mike Hawkins? They weren't insiders until they received mCig shares for their software. Don't see any logic here.
Just a correction to my previous post which I just noticed. The next 10-Q is for the three months ending 9/30/19 (not 6/30/19). Consequently, assuming they're on schedule, we should see the first deposit of approximately $1,440,000 on the quarterly financials. The other deposits may or may not appear depending on when they were (or will be) paid...
90-120 days from May 28, 2019 would give them a down payment between roughly August 28 and September 28 of approximately $1,440,000
90-120 days from July 10, 2019 would give them a down payment between September 10 and October 10 of approximately $2,160,000
90-120 days from July 31, 2019 would give them a down payment between September 31 and October 31 of approximately $8,472,834
None of these deposits are required to be on the next 10-Q which covers the three months thru 6/30/19. However, they may disclose it under subsequent events.
OK, let's do some math.
As of 9/18/2019, the Outstanding Share (OS) count was 490,189,299 shares and the total convertible debt was $1,092,878. We know this from the 9/19/19 8-K...
September 19, 2019 SIML 8-K
As of September 18, 2019, the current Issued/outstanding common shares are 490,189,299; whereas of this amount, the number of restricted shares is 103,021,354 and the number of non-restricted shares is 387,167,945. The total amounts of the notes with reserves are in value of approximately $1,092,878.
Perhaps they consulted with Satel or perhaps they had several suitors and just decided to make themselves more attractive with an RS. The RS was actually initiated on October 19 and was probably planned for several months beforehand. The Satel merger wasn't finalized until the following January. Either way, it makes no sense to blame the current management for the share structure the previous management created and had to correct.
All those reverse splits/name changes occurred under different management. The current company was actually born on 11/13/2018 just as the last RS was being completed. From the last 10-Q...
June 30, 2019 SIML 10-Q
3. MERGER TRANSACTION
On November 13, 2018, the Company, and Satel Group Inc., a Nevada corporation, entered into an Agreement and Plan of Merger (the “Merger Agreement”) and completed a merger, whereby Satel Group merged with and into Simlatus, with Satel Group remaining as the surviving entity (the “Merger”). Upon the consummation of the Merger, the shares of the common stock of Satel Group extinguished and the stockholders of the Company were issued an aggregate of 1,086,592 of the Preferred Series A stock at a price of $1.79 per share and convertible pursuant the conversion rights as specified in the Articles of Incorporation for SIML. As a result of the Merger, the Company acquired the business of Satel Group and will continue the Simlatus business.
Because the prior owners of Satel Group, Inc.’s outstanding common stock owned more than 50% of the combined voting interest in the Company, on a fully-diluted basis, immediately following the merger, the Merger is treated as a “reverse merger” under the purchase method of accounting, with Satel Group, Inc. as the accounting acquirer. Accordingly, Satel Group, Inc’s historical results of operations replace Simlatus’ historical results of operations for all periods prior to the Merger and, for all periods following the Merger, the results of operations of the combined company will be included in the Company’s consolidated financial statements.
LMAO Show us in your great wisdom exactly how Paul made money off his millions of shares going down in value over the past year. He hasn't sold a single share.
The entire MJ sector has gone down considerably over the past two years. We've all lost money. Paul is no different than the rest of us.
We have $23M in orders being manufactured with 90-120 day delivery schedules.
Clarification on CBD Extraction System Purchase Orders and Delivery
The company received purchase orders from United Opportunities LTD on May 28, 2019 and July 31, 2019 in the amounts of $2,880,000 and $16,945,668 respectively.
The company received a purchase order from Brand House Ventures Inc. on July 10, 2019 in the amount of $4,320,000.
The company is manufacturing the systems in Grass Valley, California in order to maintain quality assurance. Each system requires a 50% deposit upon successful on-site inspection, C1D1 Certification Approval, platform design needs, and process specifications based upon a needs assessment. This process can take 90-120 days depending upon State and County regulations.
Currently, the company anticipates manufacturing and delivery on or before December 15, 2019.
I wouldn't attach too much importance to December 15. That was/is a target ship date. Delays happen. First Customer Ship dates can slip at even the most established companies.
I just do not see a plausible master scam plan here where anyone gets rich.
Quarterly Report announcement...
InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
Research & Development Update:
Biosynthesis manufacturing technology. During 1Q20, we continued to optimize fermentation parameters to maximize production yield and to develop a Down Stream Purification process ("DSP") with contract development manufacturing organizations ("CDMOs"). We remain on-track to conclude these activities by the end of calendar 2019. In addition, the Company continues to work on an "alternative" biosynthetic manufacturing process with one of our CDMOs. These efforts have resulted in the filing of a provisional patent application for an enzyme which could be applied to both our traditional as well as our "alternative" biosynthesis pathways.
INM-755 for the treatment of the epidermolysis bullosa (EB). During 1Q20, InMed completed preparations for its first-in-human clinical trial, scheduled to begin by the end of this calendar year. We completed the supporting preclinical safety pharmacology and toxicology studies, set up the European manufacturer of the drug product, and designed the clinical study protocols. These efforts resulted in the November 4th submission of InMed's first ever Clinical Trial Application, or CTA, seeking permission to initiate human clinical studies with INM-755. The submission was made in parallel to the independent Ethics Committee and Dutch Regulatory Authority. We plan to initiate the trial immediately after receiving approval.
INM-088 for Glaucoma. The Company continues the development of INM-088 for glaucoma including the strengthening of our intellectual property position with the filing of an additional provisional patent application. During 1Q20, the Company completed in vitro testing of INM-088 and initiated several formulations and pharmacology studies. The Company anticipates completing these activities in early 2020.
I believe he's talking about book value not market capitalization. There's a big difference. The current price to book (P/B) ratio on InMed is 2.41x
$400,000,000 x 2.41 = $964,000,000 market cap / 172,300,000 shares OS = $5.59/share
However, the market should give InMed a higher P/B ratio once they start Phase II. If we compare to GW Pharmaceuticals, for example, whose P/B ratio is currently 5.71x the pps could be...
$400,000,000 x 5.71 = $2.284,000,000 market cap / 172,300,000 shares = $13.26/share
$500,000,000 x 5.71 = $2,855,000,000 market cap / 172,300,000 shares = $16.56/share
Of course, InMed may not receive as high a P/B ratio as GW and there will likely be additional dilution but, from this perspective, the prediction is perfectly rational.
New PR today...
ALYI – Alternet Systems Management Gets Ahead Of EV Brand Name Rumors
DALLAS, Nov. 05, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Alternet Systems, Inc. (USOTC: ALYI) management today issued a statement to get ahead of rumors that a major electric vehicle brand name has expressed interest in ALYI’s electric vehicle initiative in Africa. ALYI is developing $300 million in electric vehicle projects in Africa targeting the shared ride market. The company has signed orders to produce in Africa, electric motorcycles with a side car initially for shared ride providers in Kenya. The company successfully passed an electric motorcycle prototype testing milestone recently and anticipates having its production design pilot motorcycle completed any day. ALYI has also recently announced a $100 million cryptocurrency investment strategy targeted at expanding beyond the company’s existing $300 million in electric vehicle projects in Africa. In reaction to recent questions the company has received regarding a deal signed with a major electric vehicle brand involving a new project in Africa, ALYI management released the following statement: “Alternet Systems believes in and is committed to its electric vehicle initiative in Africa. Accordingly, we are enthusiastically developing resources to advance and expand upon our electric vehicle initiative in Africa. Our efforts to develop resources absolutely includes engaging with major brand names in the global electric vehicle market. We have made inroads with one major brand name in particular and anticipate making a joint announcement soon. Until then, we are not at liberty to comment on the specific organization nor any details regarding the nature of the potential agreement.”
For more information, please visit: www.alternetsystemsinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.
Alternet Systems, Inc. Contact:
Randell Torno
info@lithiumip.com
+1-800-713-0297
Source: Alternet Systems, Inc.
© 2019 GlobeNewswire, Inc.
That's a bit misleading without continuing your quote to the following paragraph...
SIML Will Design World’s First Hybrid CBD Extraction System
Richard Hylen, CEO, stated, “We now have the technology rights to build a CBD extraction system that can process bio-mass through a cold-water extraction processing system first, and through an alcohol extraction system second. This provides a pharmaceutical grade CBD product through the cold-water process, and an industrial CBD product through the alcohol process. We are utilizing more of the bio-mass and increasing efficiency and less waste. These processes will open doors for the larger companies to be more efficient and increase their bottom line.”
Popular definition of scam: A stock whose price has gone down since I bought it. LOL
Nice DD!
There is no way failing cable company will start making cbd extractors and have contracts already and not even make one yet.
Who is GP solutions and why are you posting about them? What's your point?
So if a diluter had that many share to sell the O/S has to be at least 1.5B
they were doing a hundred million in diluting for two straight months July and August just think where they've gone now with the huge increase in volume
Naked shorting is the illegal practice of short selling shares that have not been affirmatively determined to exist. Ordinarily, traders must borrow a stock, or determine that it can be borrowed, before they sell it short. So naked shorting refers to short pressure on a stock that may be larger than the tradable shares in the market. Despite being made illegal after the 2008-09 financial crisis, naked shorting continues to happen because of loopholes in rules and discrepancies between paper and electronic trading systems.
New PR - Message from CEO...
Armata Pharmaceuticals Issues Letter to Shareholders
MARINA DEL REY, Calif., Oct. 31, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today issued the following letter to shareholders. The letter has been made available to all existing shareholders with the Proxy for the 2019 Armata Annual General Shareholders meeting to be held on December 10, 2019.
https://mma.prnewswire.com/media/884786/Armata_Logo.jpg
To my fellow shareholders:
It has been approximately six months since we completed the merger between C3J Therapeutics and AmpliPhi Biosciences, and I am pleased to report that the complementary capabilities and synergies that we envisioned when we brought these two companies together are being realized as anticipated. We have created what we believe to be a leader in the discovery and development of both natural and synthetic bacteriophage or "phage" therapeutics to combat multi-drug resistant bacterial infections. These infections have become a global public health crisis that is leading to increased morbidity and mortality while at the same time burdening healthcare systems with significant costs.
Bacteriophage are a type of naturally occurring virus that infect and kill bacteria. Unlike antibiotics, they are targeted to kill specific strains of bacteria. Although phage therapy was discovered in the early 1900's it has not been widely used in most Western societies, especially since the introduction of antibiotics. There has been renewed interest in phage-based therapies in recent years, however, given the increased incidence of bacteria that have evolved to resist most currently available antibiotics.
The successful Key Opinion Leader meeting that we held in June featured a presentation by Robert "Chip" Schooley, MD, Professor of Medicine and infectious disease physician at the University of California, San Diego (UCSD) School of Medicine, UCSD's Senior Director of International Initiatives, and Vice Chair of Academic Affairs in the Department of Medicine. Dr. Schooley has over 30 years of experience in the development of anti-infective therapies and has led the treatment of critically ill patients using bacteriophage therapeutics under FDA-allowed Emergency Investigational New Drug applications (EINDs). It was indeed powerful to hear first-hand the positive impact that phage-based therapeutics can have in a real-world clinical setting with patients that otherwise have limited remaining options. In addition to these patients with life-threatening multi-antibiotic resistant infections, we believe there are opportunities for phage to be used in prophylactic settings to prevent infectious diseases, and perhaps other illnesses. We believe we are in the right place at the right time.
We recently announced the development of a new phage candidate, AP-PA02, to treat Pseudomonas aeruginosa. This bacterial pathogen causes difficult-to-treat respiratory infections that are particularly problematic for cystic fibrosis patients given their already compromised immune system. P. aeruginosa is widely recognized by the U.S. Centers for Disease Control and other public health agencies as among the most dangerous pathogens in terms of growing antibiotic resistance. AP-PA02 is uniquely comprised of a mixture of multiple complementary bacteriophages that provide improved host range, increased potency and superior resistance prevention. AP-PA02 is just one example of the novel candidates to emerge from Armata's robust research and development capabilities, and significantly improved upon our original P. aeruginosa phage product candidate, AP-PA01. AP-PA01 has been tested under an EIND with some promising results.
To identify AP-PA02, we screened hundreds of P. aeruginosa clinical isolates against our extensive phage library utilizing proprietary methods that identify optimal phage combinations with superior attributes. The phage product discovery platform together with our world-class phage specific GMP manufacturing facilities uniquely enable Armata to efficiently identify new therapeutic candidates. We continue to advance preclinical studies of AP-PA02 with the goal of accelerating regulatory filings and commencing human clinical trials shortly thereafter. The predecessor product to AP-PA02, AP-PA01, was recently featured in the highly regarded and peer reviewed journal Infection after being used to successfully treat a cystic fibrosis patient who had developed a multi-drug resistant bacterial infection. Based on this case study and the compelling results seen to date in preclinical studies of the improved product, we have elevated AP-PA02 to our highest priority program. We plan to initiate clinical studies in cystic fibrosis patients and obtain clinical data from our first-in-human study in 2020. We intend to also optimize a Pseudomonas phage product candidate for the treatment of bacterial pneumonia utilizing a core set of phages derived from AP-PA02, with the goal of regulatory filing and clinical entry in 2020.
Using the same proprietary techniques that we employed to improve upon AP-PA01, we have developed an improved candidate for Staphylococcus aureus, AP-SA02. Improved patient outcomes are needed for staphylococcal infections, particularly those caused by methicillin-resistant S. aureus, in settings such as bacteremia, endocarditis and prosthetic joint infections, and we believe AP-SA02 could have a meaningful impact in these indications. Given our priorities to devote internal resources to the Pseudomonas respiratory indications mentioned above, clinical trials in S. aureus indications outside of respiratory infections will not proceed until we secure third party funding. Having bacteriophage products for S. aureus and P. aeruginosa would enable us to address the two most common pathogens causing hospitalized pneumonia, therefore we plan to move AP-SA02 into respiratory clinical trials with insight gained from the Pseudomonas pneumonia studies.
In parallel with these development activities, we continue to screen additional pathogens against our phage library as we work to further expand our pipeline. Our collaboration with Merck is progressing and reflects big pharma's growing interest in phage therapy. We believe that as we identify new phage product candidates and start to receive data read outs from our clinical trials, new partnering opportunities will emerge and we would expect the market value of Armata to increase as a result.
In closing, I would like to thank the entire Armata team who have worked tirelessly to get us to this point, and you, our shareholders, for your continued support. We are just getting started, and I am excited about what the future holds for Armata. In next year alone, we believe we have multiple opportunities for value creation for our shareholders, while developing novel therapeutics that can potentially save lives. I look forward to keeping you apprised of our ongoing progress.
Sincerely,
Todd R. Patrick
Chief Executive Officer
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
As of October 11, 2019, Armata had approximately 142 shareholders of record.
Forward Looking Statements
This communication contains "forward-looking" statements, including, without limitation, statements related to successfully integrate the operations of AmpliPhi Biosciences Corporation ("AmpliPhi") and C3J Therapeutics ("C3J") and achieve the potential benefits of the merger; Armata's ability to meet expected milestones, expand its pipeline, and pursue additional potential partnerships, Armata's ability to be a leader in the development of phage-based therapeutics, and statements related to clinical trials, including the clinical trials of AP-SA01, AP-SA02 and AP-PA02 and the outcomes of any trials undertaken by Armata, Armata's ability to successfully develop new products based on bacteriophages and synthetic phages to kill bacterial pathogens and treat alternative infections, the timing and outcome of expected pre-IND meetings and IND filings, Armata's ability to expand testing of isolates from around the world and the results of those tests, the benefits of Armata's collaboration with Merck, Armata's ability to sufficiently fund its operations as expected, including obtaining additional funding as needed, and expectations for performance of Armata's therapeutic candidates based on our recent nonclinical work.
Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Armata's current expectations. Forward-looking statements involve risks and uncertainties. Armata's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Armata's lead clinical candidates, AP-PA02 and AP-SA02, to be more effective than previous candidates; Armata's ability to expedite development of AP-PA02; Armata's ability to file an IND with the FDA for AP-PA02 during the fourth quarter of 2019; Armata's ability to successfully integrate the operations of AmpliPhi and C3J and achieve the potential benefits of the merger; Armata's ability to advance its preclinical and clinical programs and the uncertain and time-consuming regulatory approval process; Armata's ability to develop products based on bacteriophages and synthetic phages to kill bacterial pathogens; Armata's expected market opportunity for its products; and Armata's ability to sufficiently fund its operations as expected, including obtaining additional funding as needed.
Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission ("SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC on March 25, 2019, Armata's Definitive Merger Proxy Statement on Schedule 14A, filed with the SEC on April 4, 2019, as amended, Armata's Definitive Proxy Statement on Schedule 14A, filed with the SEC on October 22, 2019, Armata's Quarterly Reports on Form 10-Q filed with the SEC on May 6, 2019 and August 14, 2019, and Armata's subsequent filings with the SEC. Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
Steve Martin
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
(858) 800-2492
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
https://c212.net/c/img/favicon.png?sn=LA20808&sd=2019-10-31 View original content to download multimedia:www.prnewswire.com/news-releases/armata-pharmaceuticals-issues-letter-to-shareholders-300948349.html
SOURCE Armata Pharmaceuticals, Inc.
The extractors are being built by Lave, Inc. which appears to be owned by BrewBilt, Inc (in partnership with SIML) which is a manufacturer of fermentation vessels and equipment for breweries...
SIML – Proscere Bioscience Announces CBD Extraction Expansion
San Francisco, California, Aug. 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) (“Simlatus” or the “Company”) announces today that it has finalized negotiations with Lave, Inc. to expand its current manufacturing processes in order to complete all purchase orders for its Cold-Water CBD Extraction systems. While acquisitions of companies in the hemp sector accelerate worldwide as industrial and consumer hemp/CBD markets develop, our Proscere Bioscience is the company’s division focused on the CBD industry with sales of over $23M during the first half of 2019 for its Cold-Water Extraction System and its new hybrid Cold-Water/Alcohol Combine Extraction technology. Distribution channels cover North America and Europe.
Richard Hylen, CEO and Chairman, stated, “The company is currently setup to manufacture and deliver its extraction systems utilizing a strategic partnership with Lave, Inc. This offers our Proscere Division a more streamlined 20,000 sq. ft. facility to perform manufacturing processes, assembly and testing before delivering the systems to our customers. We have $23M in orders being manufactured with 90-120 day delivery schedules. We also have potential orders of $74M that we are closing in the near future.”
Mr. Hylen further stated, “Our systems provide cannabis farms, processing plants and retailers the ability to capture over 90% product from the bio-mass with more efficiency, speed and higher grade. Proscere Bioscience is now the leader in this technology and is attracting the big players in the cannabis industry.”
This JEFFERY HOWARD LEWIS character is apparently the owner of a company which manufactures custom metal brewing equipment aka BrewBilt, which has the same physical address in Grass Valley as the puported LAVE
and apparently, this is "possibly" the same person who was spoken to on the phone today by ihub user tommy_nelson_530 who said he spoke with a "Jesse" and this Jesse character reportedly could not comment about current or ongoing business he may or may not have with SIML
None of those parties can afford long court battles right now. They'll either settle their differences (maybe they already have) or just let the lawsuits die from inaction.
They've had a really bad string of luck since late 2017. Lawsuits from installing Chinese made greenhouses in Nevada that weren't up to code. FarmOn breaching their contract with mCig and not delivering product. Auditors not getting the job done. Revenue has dropped from $7 million/yr (in FY2018 thru 4/30/2018) down to around what I guestimate to be $2 million in FY2019 (thru 4/30/19). I think they're poised for a turnaround but it may take a year or two to get back to where they were. JMO
Can anyone explain the string of odd lot sales that happen periodically. We just opened with four trades of 9 shares each. We closed yesterday with one trade of 9 shares and 22 trades of 10 shares each. I've also seen strings of trades for 11 shares each and a few other share counts. More MM games??
A better question might be why in the world you would think this is BS if the CEO (who is 72 years old and has a record of working with large successful companies) would risk his fortune and reputation if he can "get fined or worse". It's definitely illegal to lie on SEC reports.
The fact that SIML gave them exclusive distribution rights in the US leads me to believe that they have solid sales orders.
Brand House Ventures, Inc is a distributor for SIML (i.e. they sell product, take orders, arrange to deliver the product, invoice and collect the money and pay their vendor - in this case SIML). They have four units on order. Apparently, they've sold four systems. The company has been in business since 2007 and has derived its revenue from management consulting. It's not hard to believe that they've used their consulting contacts to sell extractors. It would only take one good sales rep to sell 4 extractors (we don't know how many end customers ordered those four units, they could all be going to one customer for all we know).
C'mon, another "company" made with funds from the ICO, so that ALYI can then contract them to make the bikes..?
Looks like ALYI ammended today's PR...
ALYI – Alternet Systems Highlights Hemp Developments Included In $100 Million Cryptocurrency Investment Strategy Press Release | 10/28/2019
DALLAS, Oct. 28, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Alternet Systems, Inc. (USOTC: ALYI) today highlighted that its previously announced hemp initiatives are included in the latest developments surrounding a $100 million cryptocurrency investment strategy targeted at expanding the company’s existing $300 million in electric vehicle projects in Africa.
ALYI initiated an ongoing hemp battery development initiative approximately one year ago. More recently, the company announced a hemp body initiative in conjunction with its longer-term plans to build electric delivery vehicles for the African market. The company today confirms that both the hemp battery and hemp body initiatives are include in the developing $100 million cryptocurrency investment strategy.
IW Global has proposed launching and managing an Initial Coin Offering (ICO) on ALYI’s behalf specifically targeted at raising $100 million to fund infrastructure for electric vehicle production in Africa.
IW Global ( www.IW-Global.com ), a well-established technology firm with a wide breadth of experience spanning projects for NASA and more recently implementing multiple blockchain solutions, has proposed launching and managing an Initial Coin Offering (ICO) on ALYI’s behalf specifically targeted at raising $100 million to fund infrastructure for electric vehicle production in Africa.
ALYI continues to develop $300 million in electric vehicle projects in Africa targeting the shared ride market and recently confirmed a fleet order for an initial 50 electric motorcycles to be delivered in Texas. The company successfully passed an electric motorcycle prototype testing milestone recently and anticipates having its production design pilot motorcycle completed any day. The production design plans have already been approved by partners, vendors and clients. Management plans to produce and publish a short video of the production electric motorcycles once the production version is finalized.
ALYI and IW Global have formulated a plan whereby, ALYI’s production and marketing partners in Kenya will form a new company (NewCo) with the specific focus of building a new, state of the art electric vehicle production plant. This NewCo will be a separate company apart from ALYI but exclusively contracted by ALYI for producing ALYI designed vehicles. The NewCo is the business entity that would initiate the proposed ICO. The funds would be dedicated to 1. Building the plant and 2. Funding the production of ALYI’s vehicles. A successful ICO would permit ALYI to substantially accelerate and expand upon its initial $300 million in existing electric vehicle projects.
ALYI has engaged legal counsel to ensure the cryptocurrency launch would be executed in compliance with prevailing regulatory guidelines.
ALYI has engaged Goldman Small Cap Research to conduct a survey with first time and experienced cryptocurrency investors in conjunction with a potential $100 million initial coin offering (ICO) that would provide strategic financing to fund a major expansion of the company’s electric vehicle developments.
Ethereum is the proposed underling platform for the ALYI cryptocurrency launch. The Ethereum platform and blockchain is the most reliable existing blockchain and is supported by the Ethereum Foundation, based in Zug, Switzerland and the Ethereum Enterprise Alliance based in the USA with members like Microsoft, Intel, Mastercard, UBS, BBVA, Banco Santander, among others. IW Global is experienced with Ethereum and has launched previous cryptocurrencies build on the Ethereum platform.
ALYI management plans to publish continued progress reports as the ICO strategy develops.
For more information, please visit: www.alternetsystemsinc.com
don't expect the PPS of ALYI to increase much. All the money from the ICO will be funneled in.
Interest will come when there are some new verifiable facts. Right now we can't even confirm that there was dilution and if so, how much. We'll see a new 10-Q (3FQ19 financials) by around mid November. That should move the pps one way or another if it doesn't move from some news before then.
I'm not a true believer but so far I haven't seen convincing evidence that this is a scam. Give me some real facts not speculation and misinterpretations of PR's.